Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$0.0 - $26.99 $0 - $78.5 Million
-2,910,023 Closed
0 $0
Q4 2022

Feb 14, 2023

BUY
$24.03 - $27.02 $21.5 Million - $24.1 Million
893,665 Added 44.32%
2,910,023 $78.5 Million
Q3 2022

Nov 15, 2022

SELL
$11.6 - $20.44 $2.49 Million - $4.39 Million
-214,996 Reduced 9.64%
2,016,358 $36.2 Million
Q2 2022

Aug 15, 2022

SELL
$7.78 - $14.69 $8.59 Million - $16.2 Million
-1,103,581 Reduced 33.09%
2,231,354 $27.7 Million
Q1 2022

May 16, 2022

BUY
$11.38 - $16.4 $5.29 Million - $7.62 Million
464,627 Added 16.19%
3,334,935 $44.4 Million
Q4 2021

Feb 14, 2022

BUY
$14.31 - $23.87 $8.36 Million - $14 Million
584,449 Added 25.57%
2,870,308 $44.7 Million
Q3 2021

Nov 15, 2021

SELL
$18.94 - $26.99 $169,664 - $241,776
-8,958 Reduced 0.39%
2,285,859 $51.3 Million
Q2 2021

Aug 16, 2021

BUY
$17.07 - $24.56 $36 Million - $51.8 Million
2,109,302 Added 1137.0%
2,294,817 $52.3 Million
Q1 2021

Jul 09, 2021

BUY
$20.46 - $25.18 $1.41 Million - $1.74 Million
69,061 Added 59.3%
185,515 $3.82 Million
Q1 2021

May 17, 2021

BUY
$20.46 - $25.18 $437,844 - $538,852
21,400 Added 22.51%
116,454 $2.4 Million
Q4 2020

Feb 16, 2021

BUY
$13.8 - $27.62 $79,488 - $159,091
5,760 Added 6.45%
95,054 $2.63 Million
Q3 2020

Nov 10, 2020

BUY
$14.05 - $22.6 $86,421 - $139,012
6,151 Added 7.4%
89,294 $1.26 Million
Q2 2020

Aug 14, 2020

SELL
$7.34 - $20.84 $21,520 - $61,102
-2,932 Reduced 3.41%
83,143 $1.71 Million
Q1 2020

May 11, 2020

BUY
$6.55 - $14.76 $563,791 - $1.27 Million
86,075 New
86,075 $650,000

Others Institutions Holding MYOV

About Myovant Sciences Ltd.


  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.